KLK4 and prostate carcinoma: However, a recent study has shown that this cleaved peptide may be a useful target in prostate cancer immunotherapy, with the KLK4 signal peptide successfully inducing and expanding the cytotoxic T lymphocyte response more readily than PSA or Prostatic Acid Phosphotase (PAP) [42].